



18 December 2014

Information Required Under ASX Listing Rule 3.10.5A

Further to the announcement dated 17 December 2014 Novogen has raised \$4,106,250 to date of its ongoing placement. Details are as follows:

Details of issue under 10% Placement Facility under Listing Rule 7.1A

Novogen Limited (“Novogen”) provides the following information as required under ASX Listing Rule 3.10.5A in respect of the shares issued on 18 December 2014.

(a) The dilutive effect of the placement on existing shareholders is as follows:

Number of shares on issue prior to the Placement: 187,611,240

Placement issue under Listing Rule 7.1 – (14,088,876 shares)	7.5%
Placement issue under Listing Rule 7.1A – (18,761,124 shares)	10%
Total dilution as a result of the placement	17.5%

Number of shares on issue following the placement: 220,461,240

In relation to the portion of shares issued under Listing Rule 7.1A, the percentage of the post-placement capital held (in aggregate) is as follows:

- pre-placement security holders who did not participate in the placement – 100%
 - pre-placement security holders who did participate in the placement – 0%
 - participants in the placement who were not previously security holders – 100%
- (b) Novogen has attempted to raise fund through pro-rata issues, but whilst it is in a pre-clinical study phase has found the raising of money from its shareholder base and the market to not deliver enough money to continue clinical trials which are essential to the ongoing viability of the Company.
- (c) No underwriting arrangements were in place for the placement.
- (d) The commission for the placement was 7% (plus GST) of the total funds raised.

Novogen also confirms that the source of data for determining the placement issue price, which was at least 75% of 15 day VWAP as calculated under rule 7.1A.3, was E*Trade Pro.